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ABSTRACT 26 
Methods: A randomised non-blinded non-inferiority trial was conducted to determine whether treatment 27 
with an unfractionated regimen of oral prednisolone was inferior to a fractionated regimen for dogs with 28 
primary immune-mediated haemolytic anaemia.  Dogs received the same total daily dose of prednisolone 29 
as unfractionated (group 1, starting at 4 mg/kg PO once daily) or fractionated (group 2, starting at 2 mg/kg 30 
PO twice daily) doses.  Questionnaires were administered to owners to assess adverse effects and quality 31 
of life (QoL).  Endpoints included survival to eight weeks, and changes in QoL and clinicopathological 32 
parameters over time. 33 
Results:  Thirty-nine dogs were enrolled in the study, of which 5 were withdrawn and 17 were assigned to 34 
each group.  The number of cases recruited was insufficient to determine whether unfractionated treatment 35 
was inferior to fractionated.  Total serum bilirubin decreased more rapidly in dogs in group 2, whereas 36 
polydipsia improved more rapidly in group 1.  Blood pressure and score for polyuria were higher in dogs 37 
in group 2 over time, whereas lymphocyte concentration was lower. 38 
Conclusion: Administration of the same total daily dose of prednisolone as an unfractionated dose resulted 39 
in fewer adverse effects but the effect on survival could not be assessed in this study. 40 
 41 
INTRODUCTION 42 
Immune-mediated haemolytic anaemia (IMHA) is reported to be the most common autoimmune disease of 43 
dogs[1].  Despite its relative frequency, there are few published reports evaluating different forms of 44 
immunosuppressive therapy; the majority of these reports have been retrospective analyses, often based on 45 
small numbers of dogs and often failing to present essential information regarding case selection and 46 
diagnostic criteria[2]. 47 
 48 
Glucocorticoids, especially prednisolone or its prodrug prednisone, are widely considered to be the most 49 
important component of immunosuppressive therapy for dogs with IMHA.  Whereas several previous 50 
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studies have described the efficacy of glucocorticoids in the treatment of IMHA[3,4], the starting dose, rate 51 
of tapering, frequency of administration, and use of additional drugs have varied considerably among 52 
reports[2].   53 
 54 
The terminal half-life of orally administered prednisolone is approximately two hours in dogs[5], but the 55 
pharmacodynamic effects of the drug are likely to persist for longer because they depend on changes in 56 
gene transcription and protein synthesis[6,7].  The clinical effect of a glucocorticoid drug at any particular 57 
dose may be described as the product of its potency, chiefly related to its affinity for the glucocorticoid 58 
receptor, and its presence at the receptor site, which is dictated by its pharmacokinetic profile[6,8].  This 59 
relationship suggests that twice daily administration of prednisolone may increase its efficacy for 60 
management of autoimmune diseases by increasing its availability at the receptor site.  An uncontrolled 61 
observational study of people with glomerulonephritis and after kidney transplants appeared to support this 62 
notion because patients receiving twice daily fractionated doses of oral prednisolone had a decreased 63 
magnitude of proteinuria and a lesser requirement for additional immunosuppressive drugs compared to 64 
once daily dosing[9]. 65 
 66 
Conversely, more frequent administration of prednisolone results in greater adrenocortical suppression in 67 
dogs[10], and may also increase the risk of typical adverse effects, including polyuria, polydipsia, 68 
polyphagia, excessive panting, muscle weakness and muscle wastage[6].  Previous studies have not focused 69 
on the impact that these adverse effects could have on the quality of life (QoL) of the patient and their 70 
owner, even though these could have a substantial impact on the owner’s decision to pursue treatment.  71 
Thus, in conceiving this randomised trial, the authors’ aim was to compare the survival and QoL of dogs 72 
receiving a fractionated or unfractionated regimen of prednisolone.  The authors hypothesised that 73 
unfractionated administration of prednisolone would not be inferior to fractionated treatment in terms of 74 
survival but would result in both a lesser incidence of adverse effects and a more favourable QoL. 75 
 76 
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MATERIALS AND METHODS 77 
Trial design:  A randomised controlled non-inferiority trial was conducted to compare the outcome for 78 
dogs with primary IMHA treated with prednisolone using two different dose reduction protocols, with an 79 
allocation ratio of 1:1.  A non-inferiority approach was chosen for evaluation of survival because the authors 80 
did not anticipate a significant difference between treatment groups for this parameter.  When designing 81 
the study, survival to eight weeks after diagnosis was considered to be the primary endpoint, so the sample 82 
size calculation was based on this parameter. 83 
 84 
Sample size calculation:  The authors estimated that at least 28 dogs would be required in each treatment 85 
group to demonstrate non-inferiority within the lower margin of -20%, assuming a baseline mortality rate 86 
of 10% at eight weeks after diagnosis and with power (1-β) 80% and significance value (α) 0.05.  The 87 
baseline mortality rate was based on calculation of the mortality rate at the same institution among dogs 88 
that would have been eligible for this study over the period of two years (2012-2013) before recruitment 89 
began.  The sample size calculation was completed with an online tool[11].  The lower margin of -20% was 90 
selected because previous studies have reported variable mortality rates in different samples of dogs with 91 
IMHA treated at tertiary referral institutions, and the authors considered that a margin of at least 20% would 92 
be required to prove that a difference between groups was attributable to the treatment allocation rather 93 
than the expected variance for this parameter. 94 
 95 
Participants:  Client-owned dogs were recruited at a single tertiary referral veterinary hospital between 96 
April 2014 and November 2015.  Dogs were considered eligible for inclusion in this trial if they were 97 
anaemic, with a packed cell volume (PCV) of less than 35%, and if they had at least one of the following 98 
features suggestive of immune-mediated haemolysis: prominent spherocytosis on examination of a fresh 99 
blood smear by a board-certified clinical pathologist or participant in a specialist training programme, a 100 
titre of at least 1:16 in a multivalent direct antiglobulin (Coombs’) test, or persistent microscopic or 101 
macroscopic agglutination of red blood cells after dilution in saline.  Dogs were excluded if any underlying 102 
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cause of IMHA was detected after reviewing results of complete blood count (CBC), serum biochemical 103 
profile, serologic tests for endemic arthropod-borne diseases (4DX SNAP test, IDEXX), urinalysis, thoracic 104 
radiography or computed tomography (CT) and abdominal ultrasonography or CT. 105 
 106 
After inclusion in the study, dogs were randomised in a sequence generated by a random number 107 
calculator[12] to receive the same oral daily dose of prednisolone (Prednidale, Dechra Ltd) either as a single 108 
daily dose (group 1) or as fractionated twice daily treatment (group 2), followed by a recommended protocol 109 
for reduction of the dose of prednisolone over the following fifteen weeks (shown in Table 1).  The first 110 
dose reduction was always made as indicated but, after this, the decision to proceed with the recommended 111 
reduction was made by the attending clinician based on clinical status and results of follow-up tests.  The 112 
starting dose of prednisolone and increments for dose reduction were selected based on the clinical 113 
experience of the authors and the protocols that were in use at the study institution when the study was 114 
designed.  Throughout the course of treatment described, dogs in both groups received the same total daily 115 
dose of prednisolone but this dose was always administered as a larger number of fractions for those in 116 
group 2.  The owners, attending veterinary surgeons and trial co-ordinators were not blinded to the 117 
allocation of the treatment protocol.  If dogs were inappetent, they received daily intravenous injections of 118 
dexamethasone sodium phosphate (Dexadreson, MSD Animal Health; at 0.4 mg/kg per day) while 119 
hospitalised until they were able to receive oral medications.  All dogs also received azathioprine (Imuran, 120 
Prometheus Laboratories Inc or Azathioprine Capsules, Nova Laboratories Ltd; median dose 50.4 mg/m2 121 
every other day, IQR: 46.7-54.3), omeprazole (Omeprazole, Mylan; median dose 1.1 mg/kg per day, IQR: 122 
0.9-1.2), and either aspirin (Soluble Aspirin, Actavis; median dose 0.5 mg/kg per day, inter-quartile range 123 
[IQR]: 0.5-0.5) or clopidogrel (Plavix, Bristol-Myers Squibb; median dose 3.8 mg/kg per day, IQR: 3.1-124 
3.8). 125 
 126 
Dogs were considered to have discontinued their allocation if they received an additional 127 
immunosuppressive drug during the period of the study or if they deviated from the dose reduction schedule 128 
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outlined in Table 1 due to a delay of more than one week in making a reduction, due to making a more 129 
rapid reduction than recommended, or if a relapse necessitated an increased dose of prednisolone. 130 
 131 
Table 1: Outline of the prednisolone dose reduction schedules utilised in treatment groups 1 and 2. 132 
Time point after diagnosis Dose of prednisolone 
Treatment group 1 Treatment group 2 
Diagnosis 4 mg/kg PO SID 2 mg/kg PO BID 
Week 1 2 mg/kg PO SID 1 mg/kg PO BID 
Week 3 3 mg/kg PO every other day 0.75 mg/kg PO BID 
Week 5 2 mg/kg PO every other day 0.5 mg/kg PO BID 
Week 8 1 mg/kg PO every other day 0.25 mg/kg PO BID 
Week 11 0.5 mg/kg PO every other day 0.25 mg/kg PO SID 
Week 13 0.5 mg/kg PO q3 days 0.5 mg/kg PO q3 days 
Week 15 STOP STOP 
 133 
Following discharge from the hospital, measurement of the PCV was recommended prior to each dose 134 
reduction shown in Table 1, with more complete examinations at three weeks and eight weeks after 135 
diagnosis at the same institution or at the referring veterinary practice.  At these visits, procedures were 136 
recommended to monitor progress and detect any adverse effects of treatment, as shown in Table 2, and 137 
questionnaires were administered to owners to assess the QoL of the dog.   138 
 139 
Table 2: Outline of the procedures recommended at re-examination visits for dogs in both treatment groups 140 
Time after diagnosis Procedures recommended 
Week 3 CBC1, UA2, UC3, UPC4, NIBP5, bodyweight, body condition score, 
questionnaire 1 
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Week 8 CBC, BC6, UA, UC, UPC, NIBP, bodyweight, body condition score, 
questionnaire 2 
 141 
1: Complete blood cell count 142 
2: Urinalysis, including refractometric urine specific gravity, dipstick and sediment examinations 143 
3: Urine culture 144 
4: Urine protein: creatinine ratio 145 
5: Non-invasive blood pressure measurement 146 
6: Serum biochemical profile  147 
 148 
Informed consent was obtained from the owners of dogs for all procedures and for inclusion in this clinical 149 
trial.  The trial was approved by the Clinical Research Ethical Review Board at the Royal Veterinary 150 
College, University of London (reference number 2011_1134). 151 
   152 
Clinicopathological variables:  Complete blood cell counts and serum biochemical profiles were 153 
generated using instruments validated for dogs (ADVIA 2120i, Siemens and ILAB 600, Instrumentation 154 
Laboratory).  A fresh blood smear was examined by a board certified clinical pathologist with every CBC.  155 
Systolic blood pressure was measured using a Doppler probe (Model 811-B, Parks Medical Electronics Inc) 156 
after selection of a blood pressure cuff with a width that approximated 40% of the circumference of the 157 
limb of the dog.  At least three readings were obtained at every measurement; the arithmetic mean of these 158 
values was used for analysis.  All urine samples were obtained by cystocentesis under ultrasonographic 159 
guidance; bacterial culture was performed by applying 2 µl of urine to Columbia agar with 5% sheep blood 160 
and MacConkey agar plates using a sterile hockey stick spreader before incubating aerobically at 37oC for 161 
48 hours.   162 
 163 
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Questionnaires:  A complete copy of the questionnaires used in this trial is available in Supplementary 164 
File 1.  Briefly, each questionnaire consisted of a number of questions interrogating different aspects of the 165 
QoL of the dog (demeanour, activity levels, enthusiasm for exercise, water intake, urination, appetite, 166 
panting and muscular strength), together with a question asking the owner to rate the dog’s current global 167 
QoL, with all results expressed as a single mark on a 100 millimetre visual analogue scale (VAS).  For each 168 
aspect, owners were also asked to rate the importance of the changes they had observed; these scores were 169 
summated to produce a composite score that we described as owner QoL.  The questionnaire contained two 170 
final questions that asked owners if they felt that their normal activities were restricted as a result of 171 
administering medications and if they would treat another dog with IMHA based on their experience with 172 
the current patient.  An example of the question format is shown in Figure 1.  After explanation of the 173 
structure of the questionnaire and demonstration of the use of the VAS at the first (week three) re-174 
examination visit, the owner of the dog was allowed to complete this and the subsequent questionnaire 175 
without assistance from the attending veterinary surgeon.  After completion, the result of the VAS for each 176 
question was measured and recorded in an electronic spreadsheet by a single investigator.   177 
 178 
Outcome measures:  The primary outcome measure in the study was survival to eight weeks after 179 
diagnosis; additional outcome measures included changes in quality of life and hematologic and 180 
biochemical parameters between diagnosis and the re-examination visits, the proportion of dogs that 181 
developed bacteriuria during the first eight weeks of treatment, and the proportion that suffered a relapse 182 
during the same period.  A relapse was defined as a relative reduction in the packed cell volume of 25% or 183 
more compared to the previous visit.   184 
 185 
Changes to study design after completion of the trial:  Cases were enrolled over a period of 19 months, 186 
and the trial was closed eight weeks after the last participant was recruited.  An insufficient number of dogs 187 
were recruited to power the comparison of mortality between groups, so this outcome measure could not 188 
be assessed.   189 
9 
 
 190 
Statistical analysis:  All statistical analyses were conducted with commercial software packages (IBM 191 
SPSS Statistics for Windows, Version 20.0, IBM Corp and GraphPad Prism version 6.00 for Windows, 192 
GraphPad Software).  The two treatment groups were compared at baseline to assess whether they were 193 
equivalent with respect to parameters that may have prognostic value for dogs with IMHA: age; 194 
bodyweight; packed cell volume; platelet, neutrophil and monocyte concentrations; serum albumin, 195 
bilirubin, urea and creatinine concentrations; and serum alkaline phosphatase activity[13,14].  Variables 196 
were assessed for normality using the Shapiro-Wilks test.  Normally distributed variables were then 197 
compared using Student’s t test, whereas non-normally distributed variables were compared with the Mann-198 
Whitney U test.  Categorical proportions were compared with the Chi squared test or Fisher’s exact test.   199 
 200 
Changes in parameters over time and differences between treatment groups were assessed with linear mixed 201 
effect models according to the intention to treat.  Case identity was included as a random factor, whereas 202 
time point, treatment group and an interaction term between these two variables were included as fixed 203 
categorical factors.  If the interaction term was significant in any model, post hoc tests were conducted to 204 
assess the cause of this interaction.  Residuals were assessed visually and using Shapiro-Wilks test: if these 205 
were not normally distributed, the dependent variable was logarithmically transformed. 206 
 207 
The manuscript was prepared according to the CONSORT template for reporting of randomised controlled 208 
trials[15, 16] (Supplementary File 2) and all results from the trial are available in Supplementary File 3. 209 
 210 
RESULTS 211 
Thirty-nine dogs were considered eligible for the study and were randomised to treatment group 1 (n=20) 212 
or 2 (n=19).  Of these dogs, five were withdrawn from subsequent analysis because they did not survive for 213 
long enough to receive oral medications (n=2), or because they received a different combination of 214 
immunosuppressive medications from the outset of their treatment (n=3).  The remaining cases were 215 
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included in the analysis (n=17 in each group), even if they subsequently deviated from the intended 216 
treatment protocol.  Flow of cases in the trial is shown in Figure 2. 217 
 218 
There were no significant differences between groups 1 and 2 at enrolment in terms of age, sex distribution 219 
or selected haematological and biochemical parameters (as shown in Table 3), apart from a difference in 220 
urine specific gravity, which was greater in dogs in group 1 (mean 1.034, SE: 0.003) than in group 2 (1.026, 221 
0.002, p=0.047).  Nine dogs (52.9%) in group 1 and 8 (47.1%) in group 2 had received immunosuppressive 222 
drugs for up to 3 days prior to referral to the study institution; there was no difference in the proportion of 223 
dogs that had received this treatment (Chi squared, p=0.598). 224 
 225 
Table 3: Demographic, hematologic and biochemical parameters at baseline in treatment groups 1 and 2. 226 
Parameter  Treatment group 
1 (n=17) 
Treatment group 
2 (n=17) 
P value 
Age (years) Median (IQR1) 8.0 (4.1-9.0) 7.0 (3.5-8.5) 0.259 
Sex (N)    0.600 
 Male entire 1 0  
 Male neutered 6 8  
 Female entire 1 2  
 Female neutered 9 7  
Previous 
immunosuppressive 
treatment 
N (%) 9 (52.9) 8 (47.1) 0.598 
Duration of previous 
immunosuppressive 
treatment (days) 
Median (IQR) 1 (0-1.5) 0 (0-1.0) 0.817 
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Bodyweight (kg) Median (IQR) 11.4 (9.3-24.4) 15.6 (7.6-22.0) 0.734 
Serum albumin 
concentration (g/l) 
Mean (SD) 2 30.6 (6.5) 31.5 (4.8) 0.643 
Serum bilirubin 
concentration (µmol/l) 
Median (IQR) 10.5 (1.9-26.1) 13.0 (8.6-30.2) 0.491 
Serum urea 
concentration (mmol/l) 
Median (IQR) 7.9 (5.2-10.3) 7.5 (5.3-10.6) 0.809 
Serum creatinine 
concentration (µmol/l) 
Mean (SD) 56.0 (12.0) 55.6 (11.6) 0.929 
Serum alkaline 
phosphatase activity 
(U/l) 
Median (IQR) 181.0 (112.5-
407.0) 
203.0 (152.5-
222.5) 
0.724 
Packed cell volume 
(%) 
Median (IQR) 16.0 (11.0-18.0) 13.0 (10.0-17.0) 0.658 
Platelet concentration 
(x109/l) 
Mean (SD) 314 (238) 270 (137) 0.513 
Neutrophil 
concentration (x109/l) 
Median (IQR) 20.4 (12.5-28.6) 16.8 (12.5-19.3) 0.357 
Monocyte 
concentration (x109/l) 
Median (IQR) 1.77 (1.17-2.38) 1.38 (0.85-2.50) 0.474 
Lymphocyte 
concentration (x109/l) 
Median (IQR) 1.19 (0.67-2.17) 0.77 (0.66-1.53) 0.290 
Urine specific gravity 
(kg/l) 
Mean (SD) 1.034 (0.011) 1.026 (0.009) 0.047 
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Urine protein: 
creatinine ratio 
Median (IQR) 0.84 (0.57-5.79) 1.39 (0.30-2.29) 0.792 
Systolic blood pressure 
(mmHg) 
Mean (SD) 155 (26.0) 181 (27.3) 0.077 
 227 
1: Inter-quartile range 228 
2: Standard deviation 229 
 230 
No dogs in the study were lost to follow-up within the first eight weeks after diagnosis.  One dog in 231 
treatment group 2 suffered a relapse, when the PCV decreased by 50.0% eleven days after the first re-232 
examination visit; this dog was subsequently euthanised before the second re-examination visit.  Overall, 233 
two dogs in treatment group 2 (2/17, 11.7%) were euthanised within eight weeks of diagnosis, whereas all 234 
dogs in treatment group 1 survived.   235 
 236 
Six dogs in treatment group 1 and four in group 2 discontinued their allocated intervention (as shown in 237 
Figure 2).  Two dogs began to receive ciclosporin (at 5 mg/kg PO SID and 5 mg/kg PO BID) in addition to 238 
their other drugs due to perceived lack of response to treatment, whereas eight dogs deviated from the 239 
intended dose reduction schedule.  In six cases, this was due to a delay of more than one week in completing 240 
a planned dose reduction owing to inadequate control of disease (n=1), delayed presentation for re-241 
examination (n=2), incorrect instructions given to owners (n=2), or need to repeat a blood sample to assess 242 
clinical progress (n=1).  In one further dog, the dose of prednisolone was decreased more rapidly than 243 
recommended because adverse effects were considered to be particularly severe, and the remaining dog 244 
received an increased dose of prednisolone due to relapse (described in the preceding paragraph).  There 245 
was no difference between groups in the proportion of dogs deviating from the intended dose reduction 246 
schedule (Chi squared, p=0.71).  Of the dogs that were treated per protocol, none died in group 1 (n=11) 247 
and 2/13 (15.4%) were euthanised in group 2.   248 
13 
 
 249 
The median time between diagnosis and the week 3 re-examination visit was 24 days for dogs in group 1 250 
([inter-quartile range [IQR]: 20-25) and 22 days for group 2 (IQR: 20-24).  The median time from diagnosis 251 
until the week 8 visit was 59 days for dogs in group 1 (IQR: 56-66) and 60 days for group 2 (IQR: 56-65).  252 
There was no significant difference between treatment groups for these times (Mann-Whitney U tests, 253 
p=0.217 and p=0.948, respectively). 254 
 255 
Linear mixed effect models were constructed to evaluate the separate effects of the treatment allocation and 256 
time on clinicopathological parameters and QoL scores (Tables 4 and 5).  For QoL scores, data were 257 
available for 11 dogs in group 1 and 7 in group 2.  There was a significant interaction between time and 258 
treatment group for serum total bilirubin concentration (TBil) and for the VAS scores for polydipsia and 259 
panting.  The score for polydipsia decreased significantly for dogs in treatment group 1 between the first 260 
and second re-examination visits, but not for dogs in group 2 (Figure 3A).  Conversely, the TBil decreased 261 
significantly in treatment group 2 but not 1 between the point of diagnosis and the second re-examination 262 
visit (Figure 3B).  Despite a significant interaction for panting, post hoc tests did not reveal any significant 263 
differences between groups over time (data not shown). 264 
 265 
Table 4: Results of linear mixed effect models for clinicopathological variables, expressed as p values for 266 
treatment group, timepoint and their interaction term.  Significant results are highlighted in bold. 267 
Parameter Treatment group Timepoint Treatment 
group*Timepoint 
Bodyweight1 (kg) 0.581 <0.001 0.822 
Packed cell volume1 (%) 0.650 <0.001 0.887 
Lymphocyte concentration1 
(x109/l) 
0.028 0.100 0.746 
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Urine specific gravity (l/kg) 0.592 0.053 0.111 
Urine protein: creatinine 
ratio1 
0.787 0.128 0.975 
Serum total bilirubin 
concentration1 (µmol/l) 
0.609 <0.001 0.017 
Systolic blood pressure 
(mmHg) 
0.019 0.159 0.431 
1: Variable log-transformed for analysis. 268 
 269 
Table 5: Results of linear mixed effect models for visual analogue scores, expressed as p values for 270 
treatment group, timepoint and their interaction term.  Significant results are highlighted in bold. 271 
Visual analogue score Treatment group Timepoint Treatment 
group*Timepoint 
Lethargy1 0.195 0.494 0.242 
Activity 0.151 0.228 0.754 
Restlessness1 0.910 0.571 0.948 
Polydipsia 0.354 <0.001 0.045 
Polyuria1 0.031 0.006 0.160 
Polyphagia 0.232 0.025 0.302 
Panting 0.951 0.216 0.033 
Musculoskeletal strength1 0.589 0.054 0.969 
Global quality of life1 0.885 0.216 0.167 
Owner quality of life 
(summated score) 
0.690 0.919 0.576 
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Owner restriction of 
activity score 
0.110 0.357 0.733 
Owner decision to treat 
another dogs with IMHA 
0.194 0.214 0.697 
1: Variable log-transformed for analysis. 272 
 273 
The mean systolic blood pressure and polyuria score were greater in dogs in treatment group 2 compared 274 
to group 1 across time points, whereas the lymphocyte concentration was greater in group 1 (Figure 4A-C).  275 
The PCV increased for dogs in both treatment groups over time, whereas the scores for polyuria and 276 
polyphagia decreased in both treatment groups (Figures 4B-C and 5A-B).  Changes in bodyweight over 277 
time were more complex, with an overall decrease from diagnosis to the first re-examination visit, followed 278 
by an overall increase between this and the second re-examination visit (Figure 5C). 279 
 280 
There were no associations between treatment group, time, or their interaction term for the three scores 281 
used to assess owner QoL.  Three dogs in each treatment group were diagnosed with subclinical bacteriuria 282 
within the first eight weeks of treatment; there was no difference in prevalence between groups (Fisher’s 283 
exact test, p=1.000). 284 
 285 
DISCUSSION 286 
This study represents the first report of a clinical trial intended to compare two different protocols for 287 
administration of glucocorticoids in dogs with an immune-mediated disease, and the first to provide a 288 
detailed and prospective account of the adverse effects experienced by these dogs and their owners during 289 
their treatment.  Administration of an unfractionated dose of prednisolone resulted in more rapid 290 
improvement in the severity of polydipsia, as assessed with an owner questionnaire.  Conversely, dogs 291 
receiving a more fractionated dose had significantly greater reductions in serum TBil over the course of the 292 
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study compared to those receiving a less fractionated dose.  Across all time points where they were 293 
measured, dogs receiving a more fractionated dose had higher systolic blood pressures and had more severe 294 
polyuria.  It was not possible to assess the effect of the two regimens on survival to eight weeks after 295 
diagnosis because an insufficient number of dogs was presented to our institution during the period of time 296 
available for the study.  This study provides important data on the occurrence of adverse effects associated 297 
with the use of glucocorticoids and will act as a pilot study for larger trials that seek to determine the effect 298 
of dose fractionation on survival.   299 
 300 
The rate of deviation from the recommended treatment protocols was greater than expected in this study 301 
and represents a major source of potential bias.  The authors have the impression that these deviations were 302 
largely attributable to communication problems among the trial co-ordinators, other attending veterinary 303 
surgeons, and the owners of the dogs included in this study.  These observations highlight the importance 304 
of explicit and intensive communications when conducting prospective studies that involve a relatively 305 
large number of stakeholders.   306 
 307 
Beyond the known deviations from the treatment protocol, the authors did not assess whether owners were 308 
administering tablets as directed by asking them to keep a medication diary or counting the number of 309 
tablets remaining at each visit.  This may have been important in a study comparing fractionated and 310 
unfractionated regimens because more frequent administration may have been more difficult for some 311 
owners, resulting in decreased compliance.  Owner compliance with medication has not been studied 312 
extensively in veterinary medicine: a previous study of administration of antimicrobials suggested that only 313 
27% of owners gave the prescribed number of doses, but the average number of doses administered did not 314 
differ between owners of dogs receiving medications two or three times per day[17].  A further study 315 
reported similar compliance among owners administering antimicrobials once or twice daily, with a 316 
significantly greater number of doses missed if the frequency increased to three times daily[18].   317 
 318 
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Neither owners nor veterinary surgeons were blinded to the treatment allocation in this study, which 319 
represents a potential source of bias.  The decision not to impose blinding was made because dogs with a 320 
life-threatening disease were being treated by several different veterinarians, and the authors felt it was 321 
important that owners were aware of the medications their dogs were receiving in case of emergency.   322 
 323 
There was a more rapid reduction in the TBil in dogs receiving a more fractionated dose of prednisolone 324 
compared to those receiving a less fractionated dose, which may be partly related to the non-significant 325 
trend for greater pre-treatment concentrations in the former group.  This finding is of interest because TBil 326 
has been identified as a negative prognostic factor for dogs with primary IMHA in a number of previous 327 
studies[4,19,20].  Serum bilirubin concentration at any moment in time is the product of many different 328 
factors, several of which could be perturbed in dogs with IMHA.  Conversion of haem to biliverdin in 329 
erythrophagocytic macrophages is catalysed by haem oxygenase enzymes; expression of one isoform is 330 
induced directly by glucocorticoids[21].  The difference in rate of change of TBil between groups observed 331 
in this study could therefore reflect the direct effect of prednisolone on bilirubin production, as also 332 
suggested in a trial comparing two different doses of hydrocortisone in people with pituitary 333 
insufficiency[22], which reported higher serum concentrations with a larger dose.  Conversely, the 334 
difference in rate of change could indicate the severity of ongoing abnormal erythrophagocytosis, which 335 
may be fully compensated by accelerated erythropoiesis in dogs that have recovered from an acute crisis.   336 
 337 
The serum TBil concentration was measured 8 weeks after starting treatment because the authors sought to 338 
achieve a feasible balance among several factors, including the need for monitoring for possible adverse 339 
effects associated with treatment, the intention to determine whether clinicopathological factors differed 340 
between treatment groups, and the financial cost borne by the owners of enrolled dogs.  Ideally, the serum 341 
TBil concentration would have been measured more frequently and at an earlier time-point to gain a greater 342 
understanding of the kinetics of this variable in both treatment groups. 343 
 344 
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Several adverse effects, including polyphagia, polyuria, and polydipsia decreased with time in one or both 345 
treatment groups, which was anticipated with the gradual tapering of the dose of prednisolone.  There was 346 
also a difference in the rate of improvement of polydipsia between treatment groups, suggesting that 347 
fractionated administration of prednisolone results in more severe adverse effects in dogs compared to 348 
unfractionated dosing.  Alternatively, the difference in severity of polydipsia could have been affected by 349 
the observed difference in urine specific gravity at the beginning of the trial, which was significantly higher 350 
in dogs receiving a less fractionated dose.  This may indicate that dogs receiving a more fractionated dose 351 
had more severe polyuria and polydipsia from the point of diagnosis, though the authors cannot produce 352 
any feasible explanation for this difference because the two groups appeared to be similar with respect to 353 
the other parameters compared.  No difference was identified in the rate of improvement of polyuria 354 
between groups, which could be related to differences in owner observation of drinking and urination.    355 
 356 
The effect of dose fractionation on adverse effects was further supported by evaluation of the lymphocyte 357 
concentration, because exposure to glucocorticoids in vitro causes these cells to undergo apoptosis[7] and 358 
limits their capacity to proliferate in response to concavalin A[23].  In this study, there was no difference 359 
in lymphocyte concentration between groups at diagnosis but the concentration was significantly lower in 360 
dogs receiving a more fractionated dose when all timepoints were considered, confirming that greater 361 
availability of the drug at the glucocorticoid receptor did produce biological effects.    362 
 363 
This trial had some limitations in addition to those described in the preceding paragraphs.  Many of the 364 
outcome variables relied on subjective opinions provided by owners, and these may have been biased for 365 
several reasons.  For example, owners were not asked if they had experience of administering 366 
glucocorticoids to dogs before, or whether they usually spent the day at home with their dog, both of which 367 
simple factors could have influenced their perception of the severity of adverse effects.  Finally, p values 368 
were not adjusted to account for multiple comparisons between groups due to the limitations inherent to the 369 
Bonferroni method[24].  As recommended by Perneger[24], only those tests that were of greatest a priori 370 
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importance were performed, rather than comparing groups with respect to every possible 371 
clinicopathological variable.  In addition, the results obtained in this study are biologically plausible and 372 
can be interpreted easily, which largely abolishes the need for p value adjustment. 373 
 374 
In conclusion, an unfractionated regimen of prednisolone produced more rapid amelioration of adverse 375 
effects compared to a fractionated regimen, but the effect of treatment allocation on survival, if any, could 376 
not be assessed in this study because an insufficient number of dogs was recruited. 377 
 378 
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Figure 1: Example of the format of questions included in the questionnaires provided to the owners 444 
of dogs in the study.  Owners were asked to answer each question by making a single mark on the 100 445 
mm scale, as indicated in this example. 446 
 447 
 448 
  449 
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Figure 2: Flow chart of animals included in this trial, formatted according to the CONSORT 450 
reporting guidelines.  Please see reference in main text for source of this template. 451 
 452 
  453 
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Figure 3: Differences in variables over time and between treatment groups.  All graphs show means 454 
with 95% confidence intervals.  Red bars: group 1; blue bars: group 2.  The visual analogue scale for 455 
polydipsia (A) decreased significantly in dogs in treatment group 1 but not 2, whereas the total serum 456 
bilirubin concentration decreased significantly in treatment group 2 but not 1 (B).  The statistical analysis 457 
was performed using log10 values for total bilirubin; the transformation was reversed to produce this 458 
figure using model estimates. 459 
25 
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Figure 4: Differences in variables between treatment groups.  All graphs show means with 95% 462 
confidence intervals.  Red bars: group 1; blue bars: group 2.    The systolic blood pressure (A) and 463 
log(visual analogue score for polyuria) (B) were greater in dogs in group 2 compared to 1 across all time 464 
points, whereas the lymphocyte concentration was greater in group 1 over time (C). 465 
 466 
  467 
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Figure 5: Differences in variables over time. All graphs show means with 95% confidence intervals.  468 
Red bars: group 1; blue bars: group 2. The packed cell volume increased significantly over time in dogs 469 
of both treatment groups (A), whereas the visual analogue scale for polyphagia decreased in both groups 470 
over time (B). When the treatment groups were considered together, bodyweight (C) decreased from 471 
diagnosis to week 3 then increased from week 3 to 8. Note that log(visual analogue score for polyuria) 472 
and the lymphocyte concentration also decreased over time in both treatment groups, as shown in Figure 473 
4. 474 
 475 
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 476 
SUPPLEMENTARY FILES 477 
Supplementary File 1: Copy of all questionnaires used in this study.  This document contains a copy 478 
of the questionnaires administered to owners of enrolled dogs at week 3 and week 8 after diagnosis, with 479 
all questions answered by making a single mark on a 100 millimetre visual analogue scale. 480 
 481 
Supplementary File 2: CONSORT checklist.  This document contains a checklist of items that are 482 
recommended for inclusion in reports of randomised clinical trials, with the location of each item in this 483 
document noted. 484 
 485 
Supplementary File 3: Copy of all data accrued during this trial.  This document contains all clinical 486 
and questionnaire data collected for each animal enrolled in the trial. 487 
